The Molecular Oncology Training Program is a unique project at Washington University School of Medicine, designed to train graduate students and postgraduate scientists in interdisciplinary research relevant to cancer biology. From 2006 to 2010, this program supported 1 predoctoral student and 4 postdoctoral scientists each year through NIH funds, and an additional 6 predoctoral students through Siteman Cancer Center funds. The program provides 2 yrs of support for trainees to conduct laboratory research in 1 of 21 laboratories of highly experienced and productive faculty mentors. Furthermore the program includes a required spring didactic course in cancer biology, with emphasis on adult oncology or pediatric oncology in alternate years. Trainees participate in a cancer-related journal club in the fall of each year. Moreover, trainees also participate in a Clinical/Translatioal Mentoring Program each fall, occupying 1/2 day each month in one of eight areas of oncology: Medical, Radiation, Gynecologic, Pathologic, Radiologic, or Surgical Oncology, Stem Cell Transplantation, or Genomics/Proteomics/Nanotechnology. The program makes use of extensive mechanisms of evaluation by trainees, program steering committee, laboratory mentors, and internal and external advisors in order to address important areas for change and improvement.

Public Health Relevance

The Molecular Oncology Training Program supports a 2 yr period of training for graduate students working towards PhD and postdoctoral fellows with PhD who desire a broad education in interdisciplinary cancer research. Trainees participate each fall in a weekly cancer-related journal club, as well a Clinical/Translational Mentoring Program one half day per month in Medical, Radiation, Gynecologic, Pathologic, Radiologic, or Surgical Oncology, Stem Cell Transplantation, or Genomics/Proteomics/Nanotechnology. Each spring semester, trainees participate in a didactic course emphasizing adult or pediatric oncology in alternate years. Trainees also participate in a wide range of seminar programs supported by the Siteman Cancer Center, and basic laboratory cancer research with highly skilled and productive faculty mentors. The program has been jointly supported by the NCI training grant support mechanism with approximately matching funds from Siteman Cancer Center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Powell, Emily; Shao, Jiansu; Yuan, Yuan et al. (2016) p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res 18:13
Wagner, Alex H; Coffman, Adam C; Ainscough, Benjamin J et al. (2016) DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res 44:D1036-44
Kreienkamp, Ray; Croke, Monica; Neumann, Martin A et al. (2016) Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes. Oncotarget 7:30018-31
Snee, Mark J; Wilson, William C; Zhu, Yi et al. (2016) Collaborative Control of Cell Cycle Progression by the RNA Exonuclease Dis3 and Ras Is Conserved Across Species. Genetics 203:749-62
He, Zhiwen; O'Neal, Julie; Wilson, William C et al. (2016) Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells. Exp Hematol 44:161-5.e4
Xin, Jiwen; Mark, Adam; Afrasiabi, Cyrus et al. (2016) High-performance web services for querying gene and variant annotation. Genome Biol 17:91
Esser, Alison K; Schmieder, Anne H; Ross, Michael H et al. (2016) Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model. Nanomedicine 12:201-11
Su, Xinming; Esser, Alison K; Amend, Sarah R et al. (2016) Antagonizing Integrin β3 Increases Immunosuppression in Cancer. Cancer Res 76:3484-95
Griffith, Malachi; Griffith, Obi L; Krysiak, Kilannin et al. (2016) Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Exp Hematol 44:603-13
Corsa, Callie A S; Brenot, Audrey; Grither, Whitney R et al. (2016) The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis. Cell Rep 15:2510-23

Showing the most recent 10 out of 53 publications